University of Hertfordshire

From the same journal

By the same authors

Emerging drugs in Europe

Research output: Contribution to journalReview articlepeer-review

Standard

Emerging drugs in Europe. / Papaseit, Esther; Farré, Magí; Schifano, Fabrizio; Torrens, Marta.

In: Current Opinion in Psychiatry, Vol. 27, No. 4, 01.07.2014, p. 243-250.

Research output: Contribution to journalReview articlepeer-review

Harvard

Papaseit, E, Farré, M, Schifano, F & Torrens, M 2014, 'Emerging drugs in Europe', Current Opinion in Psychiatry, vol. 27, no. 4, pp. 243-250. https://doi.org/10.1097/YCO.0000000000000071

APA

Vancouver

Author

Papaseit, Esther ; Farré, Magí ; Schifano, Fabrizio ; Torrens, Marta. / Emerging drugs in Europe. In: Current Opinion in Psychiatry. 2014 ; Vol. 27, No. 4. pp. 243-250.

Bibtex

@article{b18cae699b0c4710b28bd1a3267ff28c,
title = "Emerging drugs in Europe",
abstract = "Purpose of Review: New psychoactive substances refer to emerging substances that have appeared on the market and are not under international control. NPS have been categorized in different main groups (e.g. synthetic cannabinoids, synthetic cathinones, phenethylamines, piperazines, ketamine and phencyclidine-type substances, tryptamines). This article reviews the recent literature regarding emerging trends of NPS in Europe. Recent Findings: According to the last report of the European Union Early warning system (EWS), 73 NPS were officially identified for the first time. The more frequent NPS self-reported or detected are synthetic cannabinoids and cathinones. A combination of different NPS and also mixed with other drugs, mainly cannabis and ecstasy, is usual among experienced drug users. Acute NPS toxicity includes significant psychoactive and sympathomimetic effects. Summary: This article summarizes new European epidemiological and clinical data published between January and December 2013 on NPS. In the last few years, there has been a rapid increase in the number of NPS launched on the European drugs market. The presence of some of these new substances has been detected through surveys/questionnaires, studies in drug samples and biological fluids, and case reports and NPS-induced fatalities.",
keywords = "Bath salts, designer drugs, legal highs, new psychoactive substances, research chemicals",
author = "Esther Papaseit and Mag{\'i} Farr{\'e} and Fabrizio Schifano and Marta Torrens",
year = "2014",
month = jul,
day = "1",
doi = "10.1097/YCO.0000000000000071",
language = "English",
volume = "27",
pages = "243--250",
journal = "Current Opinion in Psychiatry",
issn = "0951-7367",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - Emerging drugs in Europe

AU - Papaseit, Esther

AU - Farré, Magí

AU - Schifano, Fabrizio

AU - Torrens, Marta

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Purpose of Review: New psychoactive substances refer to emerging substances that have appeared on the market and are not under international control. NPS have been categorized in different main groups (e.g. synthetic cannabinoids, synthetic cathinones, phenethylamines, piperazines, ketamine and phencyclidine-type substances, tryptamines). This article reviews the recent literature regarding emerging trends of NPS in Europe. Recent Findings: According to the last report of the European Union Early warning system (EWS), 73 NPS were officially identified for the first time. The more frequent NPS self-reported or detected are synthetic cannabinoids and cathinones. A combination of different NPS and also mixed with other drugs, mainly cannabis and ecstasy, is usual among experienced drug users. Acute NPS toxicity includes significant psychoactive and sympathomimetic effects. Summary: This article summarizes new European epidemiological and clinical data published between January and December 2013 on NPS. In the last few years, there has been a rapid increase in the number of NPS launched on the European drugs market. The presence of some of these new substances has been detected through surveys/questionnaires, studies in drug samples and biological fluids, and case reports and NPS-induced fatalities.

AB - Purpose of Review: New psychoactive substances refer to emerging substances that have appeared on the market and are not under international control. NPS have been categorized in different main groups (e.g. synthetic cannabinoids, synthetic cathinones, phenethylamines, piperazines, ketamine and phencyclidine-type substances, tryptamines). This article reviews the recent literature regarding emerging trends of NPS in Europe. Recent Findings: According to the last report of the European Union Early warning system (EWS), 73 NPS were officially identified for the first time. The more frequent NPS self-reported or detected are synthetic cannabinoids and cathinones. A combination of different NPS and also mixed with other drugs, mainly cannabis and ecstasy, is usual among experienced drug users. Acute NPS toxicity includes significant psychoactive and sympathomimetic effects. Summary: This article summarizes new European epidemiological and clinical data published between January and December 2013 on NPS. In the last few years, there has been a rapid increase in the number of NPS launched on the European drugs market. The presence of some of these new substances has been detected through surveys/questionnaires, studies in drug samples and biological fluids, and case reports and NPS-induced fatalities.

KW - Bath salts

KW - designer drugs

KW - legal highs

KW - new psychoactive substances

KW - research chemicals

UR - http://www.scopus.com/inward/record.url?scp=84901826103&partnerID=8YFLogxK

U2 - 10.1097/YCO.0000000000000071

DO - 10.1097/YCO.0000000000000071

M3 - Review article

C2 - 24840157

AN - SCOPUS:84901826103

VL - 27

SP - 243

EP - 250

JO - Current Opinion in Psychiatry

JF - Current Opinion in Psychiatry

SN - 0951-7367

IS - 4

ER -